|
|
|
| Effect of different doses of Aspirin combined with chemotherapy on prognosis of patients with advanced colorectal cancer |
| ZHU Zhou QIN Jianing CHEN Rixin LI Jingchang LI Min GUO Xufei LIN Cheng TAN Zhenzhe NI Bingqiang |
| Department of Internal Medicine Oncology, Liuzhou People′s Hospital, Guangxi Zhuang Autonomous Region, Liuzhou 54500, China |
|
|
|
Abstract Objective To investigate the effect of different doses of Aspirin combined with chemotherapy on the prognosis of patients with advanced colorectal cancer. Methods From January 2012 to April 2013, in Liuzhou People′s Hospital, 80 patients with advanced colorectal cancer were selected, they were divided into low dose group (40 cases) and high dose group (40 cases), low dose group was given Aspirin 100 mg/d after chemotherapy, and high dose group was given Aspirin 200 mg/d after chemotherapy. The total effective rate of the two groups after treatment was compared, the progression-free survival time (PFS), 3-year overall survival rate (OS) and 5-year OS of the two groups was recorded. The serum tumor marker before and after treatment was compared, and the adverse reaction was recorded. Results Total effective rate and disease control rate in high dose group were significantly higher than low dose group, the differences were statistically significant (P < 0.05). After treatment, serum CA199 and CEA of two groups were lower than before treatment, and these of the high dose group were lower than low dose group, the differences were statistically significant (P < 0.05). PFS, 3-year OS and 5-year OS in high dose group were significantly higher than low dose group, the differences were statistically significant (P < 0.05). The total incidence of adverse reactions in high dose group was higher than low dose group, the difference was statistically significant (P < 0.05). Conclusion High dose aspirin therapy for advanced colorectal cancer patients after chemotherapy has a better curative effect, it can significantly reduce the level of serum tumor markers, improve the survival rate of patients, but there are many adverse reactions, clinical patients can choose the dose according to the specific circumstances.
|
|
|
|
|
|
[1] Kawahara H，Mouri T，Ishida K，et al. Usefulness of TAS-102 as third-line chemotherapy for metastatic colorectal cancer [J]. Anticancer Res，2018，38（4）：2419-2422.
[2] 夏秀娟，李粉婷，刘佳，等.转移性结直肠癌抗血管生成靶向治疗的研究进展[J].现代生物医学进展，2016，16（1）：187-191.
[3] Lee JH，Yoon YM，Han YS，et al. Melatonin promotes apoptosis of oxaliplatin-resistant colorectal cancer cells through inhibition of cellular prion protein [J]. Anticancer Res，2018，38（4）：1993-2000.
[4] 黄国军，王光红，高超，等.替吉奥与卡培他滨联合奥沙利铂治疗晚期结直肠癌的临床研究[J].中国临床药理学杂志，2015，31（3）：181-183.
[5] 左富义，于波，聂玉辉，等.替吉奥联合奥沙利铂与卡培他滨联合奥沙利铂方案治疗结直肠癌的疗效比较研究[J].中国全科医学，2017，20（29）：3612-3616.
[6] 王川，刘敏，李忠东，等.西妥昔单抗联合化疗药物对比单用化疗药物治疗转移性结直肠癌疗效的Meta分析[J].中国药房，2015，26（33）：4664-4668.
[7] 叶华，陈平，戴文宇，等.结直肠癌患者长期口服低剂量阿司匹林与预后关系的Meta分析[J].中华胃肠外科杂志，2015，18（6）：589-592.
[8] 苗鹏，关琳，邢承忠，等.服用阿司匹林对结直肠癌患者生存获益的Meta分析与系统评价[J].中国医科大学学报，2015，44（6）：528-532，537.
[9] 李彬，刘霞.WHO结直肠癌诊断标准在术前活组织检查病理诊断中的应用[J].临床医药实践，2013，22（11）：810-813.
[10] 王川，刘敏，李忠东，等.西妥昔单抗联合化疗药物对比单用化疗药物治疗转移性结直肠癌疗效的Meta分析[J].中国药房，2015，26（33）：4664-4668.
[11] Lee JH，Yoon YM，Han YS，et al. Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Th-rough Inhibition of Cellular Prion Protein [J]. Anticancer Res，2018，38（4）：1993-2000.
[12] 刘劲松，李丽萍，刘俊，等.复方苦参注射液联合化疗治疗对结直肠癌患者血清血管内皮生长因子的影响[J].中国老年学杂志，2014，34（2）：333-334.
[13] 周黄燕，袁敏，闵卫平，等.结直肠癌术中植入5-氟尿嘧啶缓释剂的Meta分析[J].中国药房，2017，28（3）：355-359.
[14] Sperling D，Jandorf L，Sriphanlop P，et al. Co-care：A registry for individuals at increased risk for colorectal cancer [J]. J Registry Manag，2017，44（1）：11-16.
[15] 李金明，钱江辉，吴庭玉，等.奥沙利铂白蛋白纳米粒的制备及其应用于结直肠癌腹腔化疗的研究[J].中国医药工业杂志，2017，48（12）：1751-1757.
[16] Suenaga M，Akiyoshi T，Shinozaki E，et al. A Feasibility study of Capecitabine and oxaliplatin for patients with Stage Ⅱ/Ⅲ colon cancer-ACTOR study[J].Anticancer Res，2018，38（3）：1741-1747.
[17] 许颖，谢鹏雁，王化虹，等.阿司匹林对结直肠癌的预防作用[J].中国医刊，2015，50（2）：31-35.
[18] 丁琦，孙国平.阿司匹林在结直肠癌防治中的研究进展[J].安徽医药，2016，20（10）：1827-1831.
[19] 袁晋青，徐娜.阿司匹林用于心血管疾病和结直肠癌的一级预防：美国预防服务工作组推荐解读[J].中国循环杂志，2016，31（z2）：42-44.
[20] 田赟，李楠，叶英，等.阿司匹林对结肠炎相关结直肠癌小鼠模型肿瘤细胞凋亡的影响[J].临床肿瘤学杂志，2012， 17（12）：1062-1065.
[21] 杨林承，祖凌云，高炜，等.阿司匹林在结直肠癌预防中的价值[J].中华全科医师杂志，2017，16（5）：403-406.
[22] 陈鹏，夏冬.阿司匹林预防结直肠癌的研究进展[J].肿瘤研究与临床，2018，30（2）：141-144. |
|
|
|
